NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is inviting applications for the NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for heart, lung, blood, and sleep (HLBS) disorders, under the funding opportunity number PAR-24-173. This grant program aims to support investigator-initiated Phase I clinical trials (R61/R33 mechanism) that focus on developing new diagnostic and therapeutic interventions for both adults and children, facilitating trial preparation, implementation, and necessary preclinical activities. The initiative is crucial for advancing public health outcomes by accelerating the development of effective interventions for HLBS disorders. Applications are due starting May 4, 2024, with no cost-sharing requirements, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-173.html.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.